

Elekta receives USD 64 million order for state-of-the-art linacs and Gamma Knife in Mexico

Hospital Angeles Health System to provide patients with advanced radiation therapy through acquisition of several linear accelerators

STOCKHOLM – Elekta (EKTA-B.ST) announced today that it has received an order from Hospital Angeles Health System, the largest private healthcare service provider in Mexico, to deliver state-of-the-art linear accelerators (linacs), as well as Elekta Esprit – the company’s latest Gamma Knife system – for a value of approximately USD 64 million.

With this order, Hospital Angeles Health System has shown its commitment to addressing Mexico’s cancer burden with innovative radiotherapy equipment and sophisticated software.

Elekta’s CEO, Gustaf Salford, says: “We are thrilled to announce our collaboration with Hospital Angeles Health System, a partnership that underscores our shared commitment to advancing cancer care. By combining Elekta’s cutting-edge radiation therapy solutions with Hospital Angeles’ dedication to patient-centered care, we aim to set new standards in precision radiation therapy. This collaboration will not only enhance treatment accuracy and efficiency but also ensure more people have access to life-saving technologies.”

The Hospital Angeles Health System hospital network, with more than 35 years of experience in medical and hospital care, comprises 27 hospitals nationwide, each offering state-of-the-art medical facilities and a wide range of specialized services.

The order includes software (Elekta’s MOSAIQ® oncology information system and Monaco® treatment planning system) and services. Installations will begin during the third quarter 2024/25, with the last system expected to be installed during the first quarter 2027/28. Approximately USD 38 million will be booked in Elekta’s first quarter of fiscal year 2024/25, and the first deliveries are expected in December, 2024.

###

For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CET: Central European Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it’s personal, and our global team of 4,500 employees

combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit [elekta.com](https://www.elekta.com) or follow [@Elekta](https://twitter.com/Elekta) on "X", formerly known as Twitter.

This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-01 08:55 CEST.

Attachments

[Elekta receives USD 64 million order for state-of-the-art linacs and Gamma Knife in Mexico](#)